CN120091834A - 抗体-药物偶联物及其制备方法和应用 - Google Patents

抗体-药物偶联物及其制备方法和应用 Download PDF

Info

Publication number
CN120091834A
CN120091834A CN202380073560.7A CN202380073560A CN120091834A CN 120091834 A CN120091834 A CN 120091834A CN 202380073560 A CN202380073560 A CN 202380073560A CN 120091834 A CN120091834 A CN 120091834A
Authority
CN
China
Prior art keywords
amino acid
acid sequence
antibody
seq
heavy chain
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN202380073560.7A
Other languages
English (en)
Chinese (zh)
Inventor
孟逊
刘淑惠
史静
翁炜宁
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Puzhong Discovery Pharmaceutical Technology Shanghai Co ltd
Original Assignee
Puzhong Discovery Pharmaceutical Technology Shanghai Co ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Puzhong Discovery Pharmaceutical Technology Shanghai Co ltd filed Critical Puzhong Discovery Pharmaceutical Technology Shanghai Co ltd
Publication of CN120091834A publication Critical patent/CN120091834A/zh
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6889—Conjugates wherein the antibody being the modifying agent and wherein the linker, binder or spacer confers particular properties to the conjugates, e.g. peptidic enzyme-labile linkers or acid-labile linkers, providing for an acid-labile immuno conjugate wherein the drug may be released from its antibody conjugated part in an acidic, e.g. tumoural or environment
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
    • A61K47/6803—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates
    • A61K47/68037—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates the drug being a camptothecin [CPT] or derivatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
    • A61K47/6851—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a determinant of a tumour cell
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2884—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against CD44
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • C07K16/3076—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells against structure-related tumour-associated moieties
    • C07K16/3092—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells against structure-related tumour-associated moieties against tumour-associated mucins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Cell Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
CN202380073560.7A 2022-10-19 2023-10-18 抗体-药物偶联物及其制备方法和应用 Pending CN120091834A (zh)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
CN2022126273 2022-10-19
CNPCT/CN2022/126273 2022-10-19
CNPCT/CN2023/118363 2023-09-12
CN2023118363 2023-09-12
PCT/CN2023/125253 WO2024083161A1 (en) 2022-10-19 2023-10-18 Antibody-drug conjugate, preparation method and use thereof

Publications (1)

Publication Number Publication Date
CN120091834A true CN120091834A (zh) 2025-06-03

Family

ID=90737003

Family Applications (1)

Application Number Title Priority Date Filing Date
CN202380073560.7A Pending CN120091834A (zh) 2022-10-19 2023-10-18 抗体-药物偶联物及其制备方法和应用

Country Status (9)

Country Link
EP (1) EP4605015A1 (https=)
JP (1) JP2025535447A (https=)
KR (1) KR20250080903A (https=)
CN (1) CN120091834A (https=)
AU (1) AU2023362056A1 (https=)
IL (1) IL320035A (https=)
MX (1) MX2025004492A (https=)
TW (1) TW202430221A (https=)
WO (1) WO2024083161A1 (https=)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN120369658A (zh) * 2025-06-26 2025-07-25 凯莱英生命科学技术(天津)有限公司 测定抗体偶联药物中毒素连接子的消光系数的方法及检测抗体偶联药物中药物抗体偶联比的方法

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2026037321A1 (en) * 2024-08-13 2026-02-19 Lepu Biopharma Co., Ltd. Compounds, compositions and methods

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP7381478B2 (ja) * 2017-10-23 2023-11-15 マブリンク ビオシオンス 単一分子量ポリサルコシンを含むリガンド－薬物－複合体
WO2020132190A1 (en) * 2018-12-21 2020-06-25 Multitude Inc. Antibodies specific to muc18
AU2020216780B2 (en) * 2019-01-28 2025-05-08 Multitude Therapeutics Inc. Antibodies specific to CD44
KR20220024106A (ko) * 2019-05-20 2022-03-03 노파르티스 아게 Mcl-1 억제제 항체-약물 접합체 및 사용 방법
AU2021284401A1 (en) * 2020-06-05 2023-01-05 Eisai R&D Management Co., Ltd. Anti-BCMA antibody-drug conjugates and methods of use

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN120369658A (zh) * 2025-06-26 2025-07-25 凯莱英生命科学技术(天津)有限公司 测定抗体偶联药物中毒素连接子的消光系数的方法及检测抗体偶联药物中药物抗体偶联比的方法

Also Published As

Publication number Publication date
AU2023362056A1 (en) 2025-04-24
WO2024083161A1 (en) 2024-04-25
EP4605015A1 (en) 2025-08-27
IL320035A (en) 2025-06-01
TW202430221A (zh) 2024-08-01
JP2025535447A (ja) 2025-10-24
MX2025004492A (es) 2025-05-02
KR20250080903A (ko) 2025-06-05

Similar Documents

Publication Publication Date Title
CN110841074A (zh) 抗-egfr抗体及抗体药物偶联物
WO2023102875A1 (en) Anti-cdh6 antibody drug conjugate
CN120091834A (zh) 抗体-药物偶联物及其制备方法和应用
WO2023104188A1 (en) Anti-cdh6 antibodies and antibody-drug conjugates thereof
US12496354B2 (en) CD142 antibodies, antibody-drug conjugates, preparations and uses thereof
WO2024240227A1 (en) Antibodies and antibody-drug conjugates thereof
EP4606822A1 (en) Antibody-drug conjugate, preparation method therefor and use thereof in resisting tumors
CN119053607A (zh) 喜树碱类化合物及其偶联物、其制备方法和用途
EA053275B1 (ru) Конъюгат антитело-лекарственное средство, способ его получения и применение
WO2025026338A1 (zh) 具有高药物负载的抗体-药物缀合物及其用途
CA3270684A1 (en) Antibody-drug conjugate, perparation method therefor, and anti-tumor use thereof
EA052998B1 (ru) Конъюгат антитело-лекарственное средство, способ его получения и его противоопухолевое применение
HK40107995A (zh) 抗cdh6抗体及其抗体-药物偶联物
TW202515913A (zh) Nectin-4抗體及抗體藥物結合物
BR122021021119B1 (pt) Anticorpos anti-egfr, conjugado anticorpo-fármaco, composição farmacêutica, usos dos mesmos para tratar câncer e inibir ou diminuir o crescimento de tumor sólido
BR112016021717B1 (pt) Anticorpos anti-egfr, conjugado anticorpo-fármaco, composição farmacêutica, usos dos mesmos para tratar câncer e inibir ou diminuir o crescimento de tumor sólido
BR122024015645A2 (pt) Anticorpos anti-egfr, conjugado anticorpo-fármaco, composição farmacêutica, usos dos mesmos para tratar câncer e inibir ou diminuir o crescimento de tumor sólido, bem como ácido nucleico, vetor e célula hospedeira

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
CB02 Change of applicant information
CB02 Change of applicant information

Country or region after: China

Address after: Unit 10, 159 Tianzhou Road, Xuhui District, Shanghai, 200233

Applicant after: Pu Zhong Discovery Pharmaceutical Technology (Shanghai) Co., Ltd.

Address before: Unit 10, 159 Tianzhou Road, Xuhui District, Shanghai, 200233

Applicant before: Puzhong discovery Pharmaceutical Technology (Shanghai) Co.,Ltd.

Country or region before: China